Fresenius To Upgrade I.V. Fluid Units To European Standard

Fresenius Kabi, the European leader in infusion and nutrition therapy, which has strong market presence in emerging markets including India, would upgrade its manufacturing facilities all across the world to European quality standards. As part of this global facility standardization, the company's Indian facility located at Ranjangaon near Pune is also getting upgraded to the EU quality norms.

Medtronic Offers Insulin Pumps In Indian Market

Medtronic offers Model 508 series insulin pumps to help insulin dependent patients improve their blood sugar control. In fact, maintaining near normal blood sugar levels using predictable, rapid acting insulin, delivered precisely and on command by an insulin pump can help 

Auto Disable Syringes : Hindustan Medical Devices (HMD) Tie Ups With Pharma Multinationals

Hindustan Medical Devices (HMD), the lone domestic manufacturer of auto disable (AD) syringes, is currently on a deal signing spree with many of the pharma multinationals and some of the domestic pharma companies for supply of these syringes. The pharma companies procure these syringes for free supply along with their injections as part of their campaign to promote safe injection practices.

US Pharmacopeia Sets Up India Site

The United States Pharmacopeia (USP) announced setting up its India site, consisting of its business operations and laboratories which will offer USP's broad range of Pharmacopeia services to Pharma companies in India and neighbouring countries.

Medical Devices Bill : Before Parliament Soon

The draft Bill seeking to introduce a regulatory system for medical devices used in clinical applications will be introduced in the parliament soon. The Bill with certain key provisions, was discussed by the Drug Technical Advisory Board and is forwarded by the DCC subcommittee.

Pharma Packaging : Bilcare's Expansion plan for Exports

Fitch Ratings India has assigned an 'A-(ind)' rating to Bilcare's Rs. 400-m long-term debt programme. The rating outlook is stable. The rating reflects the company's established position in the blister-packaging segment in the country, research and development (R&D) capabilities and a track record of steady growth in revenues and net cash accruals over the past few years. The company's business model is based on providing integrated solutions to its clients; from advising on the right packaging material for a particular drug to importing, processing and printing the material for the client, rather than just supplying the ordered material.